Skip to main content
Top
Published in: European Journal of Nutrition 1/2022

Open Access 01-02-2022 | Opioids | Review

A1- and A2 beta-casein on health-related outcomes: a scoping review of animal studies

Authors: Daniela Kuellenberg de Gaudry, Szimonetta Lohner, Karin Bischoff, Christine Schmucker, Simone Hoerrlein, Christine Roeger, Lukas Schwingshackl, Joerg J. Meerpohl

Published in: European Journal of Nutrition | Issue 1/2022

Login to get access

Abstract

Purpose

Food-derived bioactive peptides may influence important physiological functions. An important example is beta-casomorphins, which are opioid peptides derived from A1 beta-casein in bovine milk and have been associated to be risk factors for non-communicable diseases in humans. A1 and A2 beta-casein are different with respect to the release of bioactive peptides, in particular BCM-7. However, evidence from human studies is limited and could be complemented with evidence derived from animal studies. We conducted a scoping review to identify animal studies investigating the effects of A1 beta-casein or BCM-7 compared to A2 beta-casein or any other intervention on health-related outcomes.

Methods

We systematically searched for relevant studies in two electronic databases (Medline, Embase; last search performed March 2020). Two reviewers independently undertook study selection and data extraction of included references. Results were summarized tabularly and narratively.

Results

We included 42 studies investigating various animal models, including rats, mice, rabbits, and dogs. Six studies investigated health-related outcomes of A1- vs. A2 milk, while most studies (n = 36) reported on physiological properties (e.g., analgesic effect) of BCM-7 as an opioid peptide. Included studies were extremely heterogeneous in terms of the study population, type of intervention and dose, and type of outcome measures.

Conclusions

Only a few studies comparing the effects of A1- and A2 milk were identified. More studies addressing this research question in animal models are needed to provide essential information to inform research gaps. Results from future studies could eventually complement research for humans, particularly when the body of evidence remains uncertain as is the case in the A1- and A2 milk debate.
Appendix
Available only for authorised users
Footnotes
1
This is underestimated, since two studies provided no information on the number of animals included.
 
Literature
1.
go back to reference de Noni I, FitzGerald RJ, Hannu K, et al (2009) Review of the potential health impact of β-casomorphins and related peptides. EFSA de Noni I, FitzGerald RJ, Hannu K, et al (2009) Review of the potential health impact of β-casomorphins and related peptides. EFSA
6.
go back to reference Higgins JPT, Cochrane Collaboration (2019) Cochrane handbook for systematic reviews of interventions, Second edition. Wiley-Blackwell, Hoboken Higgins JPT, Cochrane Collaboration (2019) Cochrane handbook for systematic reviews of interventions, Second edition. Wiley-Blackwell, Hoboken
11.
go back to reference Veritas Health Innovation, Covidence systematic review software. Melbourne, Australia Veritas Health Innovation, Covidence systematic review software. Melbourne, Australia
15.
go back to reference Kaminski S, Kostyra E, Cieslinska A, Fiedorowicz E (2011) Consumption of bovine ß-casein variants (A1 or A2) does not affect basic hematological and biochemical indices. Milchwissenschaft 67:238–241 Kaminski S, Kostyra E, Cieslinska A, Fiedorowicz E (2011) Consumption of bovine ß-casein variants (A1 or A2) does not affect basic hematological and biochemical indices. Milchwissenschaft 67:238–241
25.
go back to reference Schusdziarra V, Schick R, De La Fuente A (1983) Effect of β-casomorphins on somatostatin release in dogs. Endocrinology 112:1948–1951CrossRef Schusdziarra V, Schick R, De La Fuente A (1983) Effect of β-casomorphins on somatostatin release in dogs. Endocrinology 112:1948–1951CrossRef
29.
go back to reference Dubynin VA, Maklakova AS, Nezavibat’ko VN et al (1992) Effects of systemically-administered beta-casomorphin-7 on nociception in rats. Biull Eksp Biol Med 114:284–286CrossRef Dubynin VA, Maklakova AS, Nezavibat’ko VN et al (1992) Effects of systemically-administered beta-casomorphin-7 on nociception in rats. Biull Eksp Biol Med 114:284–286CrossRef
30.
go back to reference Dubynin VA, Asmakova LS, Sokhanenkova NI et al (1998) Comparative analysis of neurotropic activity exorphins–derivatives of dietary proteins. Biull Eksp Biol Med 125:153–157CrossRef Dubynin VA, Asmakova LS, Sokhanenkova NI et al (1998) Comparative analysis of neurotropic activity exorphins–derivatives of dietary proteins. Biull Eksp Biol Med 125:153–157CrossRef
33.
go back to reference Dubynin VA, Malinovskaia IV, Beliaeva IA, et al (2008) Delayed effect of exorphins on learning of albino rat pups. Izv Akad Nauk Ser Biol 53–60 Dubynin VA, Malinovskaia IV, Beliaeva IA, et al (2008) Delayed effect of exorphins on learning of albino rat pups. Izv Akad Nauk Ser Biol 53–60
34.
36.
go back to reference Maklakova AS, Dubynin VA, Levitskaya NG et al (1993) The behavioral effects of beta-casomorphine-7 and its des-Tyr analogues. Byulleten Eksp Biol Meditsiny 116:155–158 Maklakova AS, Dubynin VA, Levitskaya NG et al (1993) The behavioral effects of beta-casomorphine-7 and its des-Tyr analogues. Byulleten Eksp Biol Meditsiny 116:155–158
38.
go back to reference Nedvidkova J, Kasafirek E, Dlabac A, Felt V (1985) Effect of beta-casomorphin and its analogue on serum prolactin in the rat. Exp Clin Endocrinol 85:249–252CrossRef Nedvidkova J, Kasafirek E, Dlabac A, Felt V (1985) Effect of beta-casomorphin and its analogue on serum prolactin in the rat. Exp Clin Endocrinol 85:249–252CrossRef
Metadata
Title
A1- and A2 beta-casein on health-related outcomes: a scoping review of animal studies
Authors
Daniela Kuellenberg de Gaudry
Szimonetta Lohner
Karin Bischoff
Christine Schmucker
Simone Hoerrlein
Christine Roeger
Lukas Schwingshackl
Joerg J. Meerpohl
Publication date
01-02-2022
Publisher
Springer Berlin Heidelberg
Keywords
Opioids
Opioids
Published in
European Journal of Nutrition / Issue 1/2022
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-021-02551-x

Other articles of this Issue 1/2022

European Journal of Nutrition 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.